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Abstract Clinical transplantology in Poland had its 50th
anniversary this year. With the early and long results
comparable to the best achieved in the world leading
centers, we face old and completely new challenges for this
medical speciality. Main and growing challenge is insuf-
ficient number of available organs. With less than
15 donors/mln population/year Poland stay in the lower
row of European countries in this measurement of trans-
plant activity. Donation system is not efficient enough and
we lose a big number of potential donors still. Living
donation (with the exception for the fragments of the liver)
remains low despite of different initiatives made so far on
the national and local levels. Donation after cardiac death
is possible from the point of Polish juridical regulations,
but since last 3 years had not showed real impact on
country donation rates (only three procedures done).
Methods of tissue typing remain slow and cause relatively
long times of cold ischemia for kidney programs. Second
main challenge is chronic rejection causing loss of organs
in the long-term follow-up and no efficient treatment
employed. The emerging possibility of tolerance induction
despite of plenty of new protocols proposition in the pub-
lications does not show up a clinical everyday practice in
work. The same is with xenotransplantation promises; even
we were informed recently that till 2030 such genetically
modified porcine organs will be available. The next chal-
lenge is production of organs and tissues from own
recipients cells installed on the different scaffolds or 3D
printed. Other challenge is the personnel working in this
field. We observe like in the other European countries lack
of new candidates for work in this field together with
serious problems of nursing staff, being a catastrophic
perspective in country medical service in general, not only
in transplant centers. The last but not least challenge is
financial side of transplant programs.
Keywords Clinical transplantation  Organ donation 
Chronic rejection  Tolerance
Introduction
Clinical transplantology in Poland had its 50th anniversary
this year. With the early and long results comparable to the
best achieved in the world leading centers, we face old and
completely new challenges for this medical speciality. In
this paper, we wanted to present the most important
problems of clinical transplantology as they are seen from
Polish perspective. Our aim was to show the new area for
scientific research for people involved in basic sciences in
immunology and immunogenetics during EWIC confer-
ence held in Wroclaw in April 2016.
The main challenges in today’s transplantology are
insufficient number of available organs, chronic rejection,
clinical implementation of tolerance induction, practical
application of xenotransplantation, regenerative medicine
using organs produced with own recipient cells, human
resources in transplantation staff, and finances involved in
transplantation programs on the country level.
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Despite many efforts Poland rate in donation measured
traditional as number of donors per million population per
year is not exceeding 15 (Malanowski and Czerwin´ski
2016). The recent tendency is showing further decrease.
The reasons for such situation are multifactorial. The first
source of organs is brain dead donors. The number of such
patients is decreasing everywhere in the world (less cranial
trauma, better medical care for cerebrovascular accident),
but still the main problem in Poland is small percent of
potential donors identification and less than 40% of hos-
pitals show any donation activity. The weak position of
transplant coordinator in most of Polish hospitals is added
to the above mention problems.
What is more the number of donors family refusals is
growing from 10 to over 20%, mainly because of negative
presentations in media—negating the brain death and
diagnostic protocols.
The second source of organs is donors after cardiac
death (DCD). It is allowed by law in Poland but the whole
procedure is ‘‘transplant effective’’ in less than 40% and
consumes a huge number of trained staff, additional
equipment and materials. Polish governmental refundation
system is not ready for such high expenses yet. As a result,
there were only three DCD procedures done in Poland
during last 3 years, when the law for such procedure was
introduced. The third source of organs (only kidneys and
liver fragments) comes from living related donors. Kidneys
from living donation in Poland represent less than 2% of
kidney transplantations. This small number comes from
high rate of potentials living donors discard ratio and social
reluctance for living donation—both from recipients, their
families and medical staff in dialysis centers. It seems that
for all above mentioned problems we need a complex and
continuous work to better adapt whole system to better
serve the still growing needs.
Chronic Allograft Rejection
Chronic allograft rejection (referred as injury or dysfunc-
tion) is a multifactorial process, which leads to allograft
fibrosis and failure. After death of a patient with a func-
tional graft, it is the second most common cause of graft
loss (except liver transplantation). Renal allograft failure is
a main cause of return of patients to dialysis treatment and
requirement for another transplant. On the poltransplant
waiting list, 30% of patients await a second or third kidney
transplant. Currently, the immunosuppressive regimens
unselectively inhibit the activity of T and B cells, by
interfering with their effector and immunoregulatory
functions and they do not fully control the chronic rejection
reaction.
Chronic allograft rejection may develop months or years
after transplantation, but the incidence increases with time
after transplantation. Our study found that chronic renal
allograft dysfunction occurred in 43% of recipients within
10 years after transplantation (Boratynska et al. 2014). The
studies from other transplant centers showed chronic allo-
graft nephropathy in 55–62% of patients after about
8 years from renal transplantation (Grinyo et al. 2011;
Marce´n et al. 2010). High incidence of chronic rejection
defined as cardiac allograft vasculopathy occurs in 25–60%
of heart recipients and as obliterative bronchiolitis in
28–80% of lung transplant patients within 5 years after
transplantation. However, chronic rejection affects only
about 4–6% of liver transplant patients.
The clinical diagnosis is suggested by gradual deteri-
oration of graft function and depends on transplanted
organ. Cardiac vasculopathy characterized by occlusive
narrowing of coronary vessels is manifested as coronary
heart disease. Chronic renal allograft injury is character-
ized by a gradual decline in glomerular filtration rate,
proteinuria and arterial hypertension (Josephson 2014;
Nankivell and Kuypers 2011).
Histological changes usually precede clinical symptoms of
chronic renal allograft injury. Wavamunno et al. (2007) found
endothelial and subendothelial ultrastructural abnormalities in
glomerular and peritubular capillaries present as early as
1 month after transplantation, and light microscopy changes
at 2.3 years in patients that many years later developed
transplant glomerulopathy. Nankivell et al. (2003) revealed
that two thirds of renal allograft fibrosis observed at 10 years
were already present in the first year after transplantation. The
common pathological changes observed in chronic renal
allograft injury are interstitial fibrosis, tubular atrophy with
accompanying vascular abnormalities (endothelial inflam-
mation and injury which leads to thickening of vessel walls by
accumulating connective tissue, mononuclear infiltration,
proliferation of myofibroblasts), and glomerulopathy (thick-
ening of glomerular capillary walls, segmental or global
sclerosis). The chronic renal allograft injury is the final path-
way of nephron injury with its fibrotic healing response
(Chapman et al. 2005).
The major mechanisms of chronic rejection involve
delayed type hypersensitivity, innate immunity, chronic
antibody-mediated rejection, and immunoregulatory
response within the graft. Wedel et al. (2015) presented
new look on the molecular events within the intragraft
microenvironment that defines the phenotype of rejection
and sustains chronic rejection process. They propose that
damage of endothelial cells resulting from ischemia
reperfusion injury, T cell cytotoxicity, and alloantibodies.
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These elicit cascade of events leading to local expression of
cytokines and several proangiogenic growth factors (e.g.,
vascular endothelial growth factor—VEGF, stromal cell-
derived factor 1) and mononuclear cell infiltration that
promote local tissue hypoxia through the transcriptional
activity hypoxia-inducible factor 1 a (HIF-1a). All these
events precede the process of endothelial to mesenchymal
transition that is associated with collagen production and
fibrosis development. VEGF plays a central pathophysio-
logical role within the allograft; it mediates vascular
remodeling and interacts with VEGF receptors on lym-
phocyte subsets. It facilitates transmigration activated T
cells and potentiates inflammation. In models of acute
rejection, antibodies to VEGF prolong graft survival. The
investigators indicated that new molecules regulated by
HIF-1a dependent path, semaphorins, and neurophilins, as
well as mTOR/Akt signaling can drive the chronic rejec-
tion process (Wedel et al. 2015).
In cardiac and renal allografts, chronic antibody-medi-
ated rejection (AMR) plays a significant role in allograft
injury and transplant loss (Colvin 2007; Costello et al.
2013; Smith and Colvin 2012). AMR is characterized by
development of donor-specific alloantibodies and histo-
logical damages. These in kidney transplant include
thrombotic microangiopathy, macrophage and granulocyte
margination in peritubular capillaries and within the glo-
meruli, and basement membrane multilamination (Colvin
2007). We and other investigators observed de novo anti-
HLA antibodies in 30–50% of patients with AMR, subse-
quently half of them lost transplant (Banasik et al. 2013;
Einecke et al. 2009; Hidalgo et al. 2009). Our data also
revealed high prevalence of non-HLA antibodies, such as
anti-endothelial cell antibodies, anti-angiotensin II type 1
receptor antibodies (anti-AT1R), and anti-endothelin
receptor antibodies (anti-ETAR) at fifth year after kidney
transplantation (Banasik et al. 2014). High levels of anti-
AT1R and/or anti-ETAR antibodies were associated with
morphological and functional allograft injury and graft loss
(Banasik et al. 2014). Simultaneous production of anti-
HLA antibodies and antibodies directed against nonpoly-
morphic antigens expressed by the graft was also found,
and could contribute to allograft destruction. This implies
that a breakdown of self-tolerance occurs during chronic
rejection and AMR is a complex interplay between allo-
and autoimmune humoral responses (Sicard et al. 2016).
Immunopathologic evidence left by antibodies is C4d
deposition in peritubular capillaries. C4d is a fragment of
C4b, an activation product of the classic complement
pathway. C4d deposition is strongly associated with cir-
culating antibodies to donor HLA class I or class II
antigens and is the marker of complement-fixing of cir-
culating antibodies to the endothelium (Bo¨hmig et al.
2002).
Noue¨l et al. (2014) showed that kidney transplant
patients with chronic antibody-mediated rejection dis-
play unique B cell phenotype with reduced ratio of
activated to memory B cells associated with an impaired
immunosuppressive activity of B cells. AMR patients
had increased number of memory B cells with poten-
tially upregulated antigen-presenting capacity and
decreased percentage and number of transitional B cells
with regulatory function. Analysis of B cell compartment
could be potentially useful as a biomarker to identify
patients at risk of AMR and a guide for therapy in the
patients with AMR.
It deserves highlighting that the mechanisms of
nephron loss resulting in chronic allograft injury comprise
not only immunologic but also non-immunologic factors,
such as ischemia–reperfusion injury, calcineurin inhibitor
nephrotoxicity, nephron mass, nonadherence to treatment,
viral or bacterial infections, proteinuria, hypertension, and
hyperlipidemia (Chapman et al. 2005; Pratschke et al.
2008).
Our studies including about 700 patients transplanted
between 1990 and 2000 suggest that factors triggering the
chronic allograft dysfunction pathomechanisms include
renal injury during the perioperative period (which mani-
fested by delayed graft function); older donor age, episodes
of acute rejection, and cytomegalovirus (CMV) infections
(Boratyn´ska et al. 2014). In the later phase of chronic
allograft injury proteinuria developed along with worsen-
ing of arterial hypertension and graft function. These are
both symptoms and risk factors of chronic injury progres-
sion, and are followed by metabolic disorders typical for
chronic kidney disease. This leads to a conclusion that
preventing graft injury during the perioperative period as
well as protecting the organ against acute rejection and
CMV infection may reduce development of chronic allo-
graft injury. Monitoring of proteinuria and implementation
of anti-proteinuric therapy, as well as treating hyperten-
sion, dyslipidemia, hyperuricemia, and metabolic acidosis
might prolong graft function (Nankivell and Kuypers 2011;
Renders and Heeman 2012). Immunosuppressive therapy is
ineffective in patients with established chronic allograft
injury.
A major barrier for improving long-term solid organ
allograft result, beside chronic rejection is death of patients
with functional graft. Collaborative Transplant Study
covering data of more than 157,000 recipients of first
kidney transplant from deceased donor transplanted
between 1985 and 2000, reported that during 5 years 17%
died but within 10 years the percentage rose to 31% of
patients (EBPG Expert Group on Renal Transplantation
2002). Three main causes of mortality in transplant recip-
ients: cardiovascular disease, infection and malignancy are
associated with side effects of immunosuppressive
Arch. Immunol. Ther. Exp. (2016) 64 (Suppl 1):S37–S45 S39
123
treatment (Chapman et al. 2013; Kahwaji et al. 2011;
Vanrenterghem et al. 2008; Watorek et al. 2011). The
induction of immune tolerance could release patients from
the need for long-term immunosuppressive treatment.
Immunologic Tolerance in Solid Organ
Transplantation
Transplant immune tolerance is a state of acceptance of
allograft without the need of maintenance immunosup-
pression while the reactivity against all other antigens
remains intact, and thus the recipient does not suffer from
immunosuppression-related infections and malignancies.
The mechanisms underlying tolerance development are
still not clear. They can be divided into these leading to
‘‘central tolerance’’ and those leading to ‘‘peripheral tol-
erance’’ and include ignorance, clonal exhaustion, anergy,
deletion and regulation. The regulation is attributed to the
regulatory cells, which can downregulate the immune
response to antigens of the donor, leading to transplant
tolerance.
Hematopoietic Stem Cell Transplantation
for Induction of Allograft Tolerance
The tolerance has been achieved in numerous animal
models of transplantation, but in human the induction of
long-term tolerance is less successful. Tolerance induction
in clinical kidney transplantation from HLA-matched or
mismatched live donors may be achieved through the
administration of donor antigens in the form of
hematopoietic stem cell (HSC) with nonmyeloablative
preconditioning approach and gradual tapering of
immunosuppression.
This strategy of development of tolerance was used by
three centers in the US: Stanford, Northwestern/Louisville
and Massachusetts General Hospital, although the proto-
cols differed in many ways (Kawai et al. 2008; Leventhal
et al. 2012; Scandling et al. 2011). The basis for allograft
tolerance applying HSC was to achieve and maintain donor
hematopoietic chimerism for long term, lasting at least
several months. However, the loss of chimerism in the
peripheral blood did not always predict or lead to graft loss.
The Stanford group recently published results of three
cohorts of total 38 patients transplanted between 2000 and
2013 (Scandling et al. 2015). Their conditioning protocol
consisted of total lymphoid irradiation (TLI) for 10 days
starting on postoperative day 1 and ATG for 5 days. Fol-
lowing the last dose of TLI, CD34?-enriched donor
peripheral blood stem cells were infused. These cells were
collected by apheresis from the donor after treatment with
granulocyte colony-stimulating factor. TLI as well as
CD34? cells were used in an increasing dose in the second
and third cohort. Additionally, CD34? and CD3? T cells
(10 and 50 times higher than in prior two cohorts,
respectively) were used in the third cohort. The chimerism
was achieved only in 7 out of the 22 patients in the second
cohort and in 2 of 10 from the third cohort. The chimerism
and relative sparing of T regulatory (Treg) versus T
effector cells contributed to the development and stability
of the tolerance. The successful withdrawal of immuno-
suppression has been achieved in 16 of 22 patients (72%)
with HLA-matched kidney.
Northwestern University trials included 29 recipients;
19 transplanted from HLA mismatched living donors and
ten from HLA-matched (Leventhal et al. 2015). In the
mismatched group, nonmyeloablative conditioning was
used [fludarabine, cyclophosphamide, and total body irra-
diation (TBI)] combined with HSC and facilitating cells—a
mixture of CD8?/TCR- to enhance engraftment and
reduce the risk of graft-versus-host disease. Twelve of 19
achieved durable chimerism and were off immunosup-
pression for more than a year, two patients lost their
allograft. The HLA-matched group received alemtuzumab
and serial infusions of CD34? cells. Microchimerism was
achieved for 1 year and 50% of patients were withdrawn
from immunosuppression. The persistent chimerism was a
better predictor of tolerance than donor-specific hypore-
sponsiveness tested in vitro.
Massachusetts General Hospital Group conducted a trial
including ten recipients transplanted from HLA-haplo
matched living donors using thymic irradiation combined
with anti-CD2 monoclonal antibodies, rituximab and
cyclophosphamide (60 mg/kg bw at day 5 and 4 before
kidney transplant) with bone marrow infusion at the day of
kidney transplantation (Kawai et al. 2008, 2013). The
patients achieved transient mixed chimerism, and in seven
patients immunosuppression had been withdrawn although
only in four patients for long term. Overall, three patients
lost their graft. In the trial most patients developed
engraftment syndrome characterized by severe acute renal
injury (Farris et al. 2011). Modified version of the protocol
with TBI replacing cyclophosphamide, to prevent
engraftment syndrome, was used in two other recipients. In
the study, deletion of donor reactive T cell clones corre-
lated with the tolerant state.
In all the presented trials, the recipients were strictly
monitored for allograft function and immune status,
including mixed leukocyte culture, cell mediated cytotox-
icity, Tregs, donor reactive T cells (high sequencing of the
T cell receptor b chain CDR3 region), quantitation of
donor chimerism. Some other registered clinical trials on
induction of tolerance in renal, liver and heart transplan-
tation are presented in Table 1.
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Table 1 Clinical trials the induction of immune tolerance in organ transplantation (ClinicalTrials.gov)
Title of study Tolerance-inducing strategy Location and sponsor
Kidney and blood stem cell transplantation
that eliminates requirement for
immunosuppressive drugs
Kidney HLA-matched from LD; conditioning:
TLI ? ATG for 2 weeks; The stem cells
(CD34) ? CD3 removed from donor will be
injected at the end of the 2-week treatment;
CsA ? MMF are stopped if stable chimerism is
achieved
Stanford University
Tolerance induction in living donor kidney
transplantation with hematopoietic stem cell
transplantation
Conditioning: 1 week prior to KT; Rituximab,
Fludarabine, Cyclophosphamide, Thymic
irradiation; Donor HSCT infused immediately
posttransplantation
Samsung Medical Center
Bone marrow transplantation and high dose
posttransplant cyclophosphamide for
chimerism induction and renal allograft
tolerance
Conditioning: ATG, fludarabine,
cyclophosphamide 14.5 mg/kg/day, TBI;
infusion of bone marrow from donor on day 0;
posttransplant: cyclophosphamide 50 mg/
kg bw on day 3 and 4; MMF and prednisone
National Institute of Allergy and Infectious
Diseases; Collaborator: ITN
Use of belatacept during post depletional
repopulation to facilitate tolerance in renal
allograft recipients
Kidney from HLA-non-identical living or
deceased donor; a single dose of alemtuzumab
on the day of transplantation; a single dose of
donor bone marrow 7 days after
transplantation; belatacept and sirolimus for
1 year
Emory University Atlanta, US;
Collaborator: Bristol-Myers Squibb
Autologous hematopoietic stem cell
transplantation for allogeneic organ
transplant tolerance; (ASCOTT)
3–6 months after liver transplantation; step 1:
chemotherapy and cytokine-based treatment for
mobilization of HSC, ex vivo purification
CD34; step 2: immune ablation (busulphan,
cyclophosphamide, ATG) prior to the infusion
of HSC
University of Toronto
Induction of donor-specific tolerance in
recipients of cardiac allografts by donor
stem cell infusion
Bone marrow processed to enrich hematopoietic
stem cells and graft facilitating cells. Donor
HSC infusion to recipient
University of Louisville; Jewish Hospital
and St. Mary’s Healthcare; Hahnemann
University Hospital; The Cleveland
Clinic
Renal transplantation followed by infusion of
T regulatory cells made with belatacept
ex vivo (the ONE Study)
Recipients of LD; administration of Treg derived
from recipient PBMC, stimulated with kidney
donor PBMC in the presence of belatacept;
measurement of Treg in the peripheral




Institute; University of Regensburg
Safety study of using regulatory T cells induce
liver transplantation tolerance (Treg)
1. Group: donor alloantigen-specific Tregs from
PB of pretransplant patients, administered
(1 9 106 cells/kg) at several intervals; 2.
Group: 1–10 year post LD liver transplantation;
isolated Tregs from these patients, and
expanded with mismatched LD antigens;
administration of donor antigen-specific Tregs
(1 9 106 cells/kg) at several intervals
Nanjing Medical University; Collaborator:
University of Minnesota
Efficacy of low dose, subcutaneous
interleukin-2 (IL-2) to expand endogenous
regulatory T cells in liver transplant
recipients
Liver transplant recipients 2–4 years
posttransplantation to receive IL-2 at dose 1.0
MIU/m2 body surface area for 4 weeks to
expand Tregs
Beth Israel Deaconess Medical Center
The ONE Study: a unified approach to
evaluating cellular immunotherapy in solid
organ transplantation—M Reg trial
Donor Mreg at dose 2.5–7.5 million cells/kg bw
infused into recipients 6–7 days before kidney
transplantation from live donor
University of Regensburg
Mesenchymal stem cells (MSC) under
basiliximab/low dose RATG to induce renal
transplant
Infusion of syngenic ex vivo expanded MSCs
(2 9 106/kg bw) at the time of kidney
transplantation from LD under basiliximab/low
dose ATG induction therapy and maintenance
CsA, MMF and prednisone
Mario Negri Institute for Pharmacological
Research, Italy
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Immunoregulatory Cells in Tolerance Induction
The alternative method of inducing of transplantation
tolerance may be the administration of regulatory cells
(Geissler 2012; Scalea et al. 2016). Several experimental
studies strongly support that tolerance is mediated by
immunoregulatory cells. Recently, there has been a great
interest in the regulatory cell-based therapy because of the
ONE Study (‘‘A Unified Approach to Evaluating Cellular
Immunotherapy in Solid Organ Transplantation’’) funded
by the European Commission’s Seventh Framework.
There, seven different regulatory cell populations have
been tested as possible routes to tolerance induction
(Geissler 2012). The allograft recipients have been treated
with a concentrated dose of well-defined regulatory
immune cells near the time of transplantation, which is
supposed to trigger a self-sustaining immune regulation.
The multicenter trial (involving clinical centers in France,
Germany, Italy, UK, and US) assesses naturally occurring
regulatory T cells (nTreg), alloantigen-driven Treg, mes-
enchymal stem cells, regulatory macrophages, dendritic
regulatory cells, and myeloid derived regulatory cells
(Elias et al. 2015). Immunosuppression protocol has been
the same at all the trial sites and includes tacrolimus,
mycophenolate mofetil and prednisone allowing compar-
ison of outcomes.
The primary interest was focused on the Tregs, whose
suppressive role in vivo is well documented and widely
discussed for two decades (Bushell et al. 1995). There are
many subsets Tregs; thymus-derived naturally occurring
Tregs are required for self-tolerance. The common feature
of Tregs is the expression of transcription factor forkhead
boxP3 (FoxP3). CD4?CD25? FoxP3 Tregs promote and
maintain allograft tolerance in animal models (Juvet et al.
2014). They induce regulatory properties in alloreactive T
cells and may prevent chronic allograft injury. Tregs utilize
multiple mechanisms to inhibit effector T cells, which
include modulation of antigen-presenting cells (APC)
function; metabolic disruption (IL-2 deprivation, adenosine
secretion); direct cytotoxicity toward effector T cells;
direct cell-to-cell interaction; and secretion of inhibitory
cytokines, such as IL-10, IL-35, and TGF-b. Tregs medi-
ated allograft response in secondary lymphoid organs and
in the graft itself (Rothstein and Camirand 2015). Tolerated
grafts are infiltrated by recipient lymphocytes that restrain
local immune responses. Moreover, Tregs within the allo-
graft may regulate tissue homeostasis and metabolism and
may contribute to tissue repair.
Investigators from Massachusetts General Hospital
found that tolerant phenotype is associated with the per-
sistence an increased proportion of
CD4?CD25?CD127-FoxP3? Treg during early post-
transplant period of induction tolerance (Andreola et al.
2011). Braza et al. (2015) reported that in tolerant
recipients the Tregs exhibited increased FoxP3 demethy-
lation of the Treg-specific demethylated region and
increased suppressive properties in vitro compared with
healthy volunteers, patients with stable allograft function
receiving immunosuppression and those with chronic
rejection.
The low quantity of Tregs in peripheral blood necessi-
tates ex vivo expansion prior to clinical use. Several
methods for the expansion of CD4?CD25?CD127low Tregs
from peripheral blood have been developed. Most proto-
cols use anti-CD3/CD28 antibodies coated to beads,
artificial APC expressing high affinity Fc, and recombinant
human IL-2. Expanded ex vivo Tregs and returned to the
patients retained Foxp3 expression that could be detected
for at least 30 days.
The first clinical study with Treg in clinical renal
transplantation was designed within the ONE Study and
entitled: ‘‘Infusion of T-Regulatory Cells in Kidney
Transplant Recipients’’. In this trial, Tregs were derived
from recipient peripheral blood mononuclear cells (PBMC)
and stimulated with kidney donor PBMC. Under these
conditions, the expansion was achieved by costimulatory
blockade. The donor-alloantigen-reactive Tregs have been
given back to the recipient 7–10 days after transplantation
(Juvet et al. 2014; Rothstein and Camirand 2015). The
study examines the safety and feasibility of administering
Table 1 continued
Title of study Tolerance-inducing strategy Location and sponsor
Third-party bone marrow-derived
mesenchymal stromal cells to induce
tolerance in liver transplant recipients
In liver transplant: a single intravenous infusion
(1–2 millions of MSCs/kg bw) of ex vivo
expanded third-party MSC (from healthy
donors)
Monia Lorini, Mario Negri Institute for
Pharmacological Research
TBI total body irradiation, TLI total lymphoid irradiation, LD living donor, KT kidney transplantation, HSCT hematopoietic stem cell trans-
plantation, Mreg regulatory macrophages, PB peripheral blood, MSC mesenchymal stromal cells, ATG anti-thymocyte globulin, CsA
cyclosporine A, MMF mycophenolate mofetil, ITN Immune Tolerance Network
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Tregs in renal transplant recipients from living donor.
Moreover, it is to define whether administration of the Treg
cell product allows for tapering of immunosuppressive
drugs within 60 weeks after transplantation. During the
period of study the presence, potency, and specificity of
Treg in the peripheral circulation of each kidney transplant
recipient has been assayed. Selected, registered clinical
trials on Tregs are listed in Table 1.
Another interesting option for cell-based tolerance
induction in human recipients is regulatory macrophages
(Mregs) (Scalea et al. 2016). Human Mregs inhibit T cell
proliferation via interferon (IFN)-c-induced indoleamine
2,3-dioxygenase activity and delete activated T cells.
Riquelme et al. (2013) reported that one dose of donor-
derived Mregs given 8 days before cardiac transplantation
in mice prolonged allograft survival in immunocompetent
recipients. Clinical trial TAIC-II (transplant acceptance-
inducing cells) assessed the safety and efficacy of admin-
istering Mreg in five recipients of living donor renal
transplant. Mregs were obtained by culturing donor
PBMCs in macrophage colony-stimulating factor and
stimulation with IFN-c followed by coculture with recipi-
ent PBMCs. The patients received induction therapy with
ATG in addition to steroid and tacrolimus. Mreg were
infused at dose 1.4–5.9 9 108 cells. A total three out of
five patients experienced allograft rejection during weaning
or after withdrawal immunosuppression (Hutchinson et al.
2008). Other clinical trials with different regulatory cells in
solid organ transplantation are presented in Table 1.
Woodward et al. (2016) presented recently an attractive
concept of the tolerance induction without the use of
chronic immunosuppression by the manipulation of the
graft, rather than the recipient. In this approach, grafts are
engineered with immunomodulatory molecules. This
technology involves changing the ratio of T effector versus
CD4?CD25?FoxP3? T regulatory cells within the graft
microenvironment. As a result, localized tolerance is
expected.
Biomarkers of Tolerance
A major factor limiting the broader clinical application of
strategies to induce tolerance is the lack of markers to
predict and identify the tolerance in patients. The reliable
markers would increase the safety of tolerance studies and
also may aid in the design of tolerance-inducing
immunosuppressive protocol. Two multicenter studies
from Europe and the US (Indices of Tolerance/RISET and
Immune Tolerance Network) including 36 patients with
operational tolerance (defined by stable graft function
despite cessation of immunosuppression for more than
1 year, usually because of nonadherence) found that these
patients have a unique pattern of cells and genes expressed
in their blood compared to other transplant patients
(Newell et al. 2010; Sagoo et al. 2010). Tolerant renal
transplant patients showed expression of multiple B cell
differentiation genes in the peripheral blood and a set of
three of these genes (TCL1A, CD20, CD79b) distinguished
tolerant from nontolerant recipients. The B cell signature
was associated with upregulation of CD20 mRNA in urine
sediment cells. In addition, the increase of total number of
B cells and defects in B cell maturation, as result of the
increase of transitional B cells (CD19?CD38?CD24?-
IgD?), naı¨ve B cells (CD19?CD27-IgD?), and memory B
cells were found. Tolerant recipients exhibited lower
number of CD4? cells, decreased production of IFN-c in
ELISPOT and high ratio of FoxP3 expression to a-1,2-
mannosidase gene expression in peripheral blood cells.
Biomarkers associated with tolerance following liver
transplantation are different. They were found to be asso-
ciated to NK cells, c/d T cells in the blood, and genes
related to iron homeostasis in the graft (Newell and Turka
2015). The tolerance biomarkers will require validation on
prospective, larger studies of transplant recipients under-
going minimization or withdrawal of immunosuppression.
The scientists participating in main clinical tolerance trials
in the report titled ‘‘Tolerance: One Transplant for Life’’
presented consensus and recommendation that make toler-
ance induction protocols a standard of care for transplant
recipients over the next decade (Kawai et al. 2014). The major
recommendations include to establish standards of registering
patients and reporting the results of tolerance trials (functional
organ status, histologic findings); to establish a standard panel
of biomarkers of tolerance; to standardize protocols for sam-
ple collection and storage; and to include children 12 years
and older into tolerance induction study.
Major impediment to progress is high costs of tolerance
trials. Costs for tolerance studies are up to 300,000 $ per
patient (it is six times higher than in drug safety and effi-
cacy trials). These account conditioning, administering
HSCT or regulatory cells, monitoring of patients, use of
nonstandard procedures and longer term of follow-up
(Kawai et al. 2014).
Many barriers exist for introduction protocols inducing
tolerance to transplant clinic. There is need of new proto-
cols, new trials that involve more centers and larger
number of patients and extend protocols of induction tol-
erance to other organs and to organs from deceased donors.
Xenotransplantation
The dream of animal organs and tissue as a transplant
material in clinical use is not young. We had such dra-
matically clinical situations in Poland also, with pig heart
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transplanted to human recipient by Religa in the lack of
human donor in the late 80s. All those early efforts con-
structed the wide field of scientific work in this domain. In
2016 ISODP Congress in Seoul, we had heard the per-
spective of 2030 to see the first animal organ transplanted
to human recipient. Progress done in genetically modified
pigs shows such perspective in a real light but does not
answer many other questions arose (Cooper et al. 2016;
Olver 2016). When most problems concerned about
immunotolerance and immunosuppression in xenotrans-
plantation seems to be possible to be solved quite soon,
than thrombogenicity and problems of unknown infectious
dangers are still before us (Cooper et al. 2016).
Regenerative Medicine
Both xenotransplantation and regenerative medicine pro-
mise to free clinical transplantation from all dilemmas
connected with human donation of organs and cells. Last
decade give us hope for such solutions. The idea of using
own recipient cells cultured on the natural or 3D printed
matrix scaffold is intensively introduced in basic science
and some models (urine bladder) are in clinical trials in
more than 10 years, with very promising results (Jung et al.
2016; Zhang et al. 2016).
Transplant Staff Burning-Out Syndrome
There are not a big number of specific papers describing
situation of transplant staff. The transplant centers in
Europe and North America are using more and more for-
eign doctors and nursing staff in transplantation and other
specialities. In clinical transplantation, the unlimited (in
practice) work time and unpredictability makes difficult to
recruit the new candidates to this field. Polish solution with
a mandatory specialization in clinical transplantology
(4–5 years of additional training) makes this problem even
more dangerous. Even without that problem, a dramatical
decrease in the nursing staff in all Polish hospitals needs
immediate and wise decisions now (Le Gall 2011).
Other challenges in clinical transplantation as organi-
zation and financing are not in the scope of this paper.
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